Gefitinib sustained-release implantation agent for curing entity tumour

A slow-release implant, gefitinib technology, applied in the field of medicine, can solve the problems of systemic toxicity and side effects limiting clinical application, limiting clinical application, cardio-liver-pulmonary system toxicity, etc.
CN101176715AInactive Publication Date: 2008-05-14JINAN SHUAIHUA PHARMA TECH
4 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
JINAN SHUAIHUA PHARMA TECH
Publication Date
2008-05-14
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

The invention relates to a gefitinib sustained-release implant capability for curing solid tumors, such as lung cancer, esophageal cancer, gastric cancer, liver cancer, breast cancer, ovarian cancer, prostatic cancer, bladder cancer, colon cancer and rectum cancer. The invention is characterized in that: the sustained-release implant comprises gefitinib, sustained-release excipient and a certain amount of sustained-release regulator; the amount of the gefitinib and sustained-release excipient is sufficient to control cancer; the sustained-release excipient is mainly one or the combination of the copolymer of glycolic acid and hydroxyacetic acid, polifeprosan, poly (L-lactide-co-ethyl phosphate) and poly (L-lactide-co-propyl phosphate); the gefitinib can be released slowly into part of the tumor during the degradation and adsorption, significantly reducing the systemic toxicity and sustaining the effective medicine concentration simultaneously. The invention has the advantages that: the systemic toxicity of gefitinib can be significantly reduced; the effective medicine concentration can be improved selectively at part of the tumor, and the therapeutic effects of non-operative treatments such as chemotherapeutic drugs and radiotherapy can be reinforced.
Need to check novelty before this filing date? Find Prior Art

Description

(1) Technical field

[0001] The invention relates to a gefitinib slow-release implant for treating solid tumors, belonging to the technical field of medicines. (2) Background technology

[0002] In the past few decades, although the research on cancer has made great progress, its mortality rate is still in the forefront of various common causes of death. The latest data show that in 2006, 3 million people died of cancer in my country. Due to the impact of environmental pollution and bad eating habits, the incidence of cancer is increasing year by year and showing a younger trend. Statistics show that in less than 20 years, the incidence of cancer in my country has increased by 69%, and the death rate has increased by 29.4%. According to the latest statistics from the World Health Organization, the global cancer incidence rate will increase by 50% by 2020, and the number of patients will increase to 15 million. It is estimated that 4 million people will die of cancer every ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More